DOCSLIB.ORG

Stable Angina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stable Angina DRUGS FOR ISCHEMIC HEART DISEASE Dr. Jyoti M. Benni Asst. Prof Dept. of Pharmacology USM-KLE, IMP, Belgaum LEARNING OUTCOMES Describe pathophysiology of IHD. Describe drug groups for angina and MI based on mechanism of action & adverse effects as therapeutics in angina and myocardial infarction. Surgical interventions – PCI, CABG INTRODUCTION Angina pectoris- Is a pain syndrome due to induction of an adverse oxygen supply/demand situation in a portion of myocardium. The primary cause of angina is imbalance in blood supply, due to: a decrease in myocardial oxygen delivery an increase in myocardial oxygen demand or both The types of angina (1)Stable angina (2)Unstable angina (3)Variant angina TYPES OF ANGINA Fixed atheromatous stenosis Exertional /Typical or classic angina underlying atherosclerosis giving rise to ischemia increased oxygen demand Anginal episodes can be precipitated by exercise, cold, stress, emotions or eating Unstable angina also known as: Preinfarction angina/Crescendo angina/ Angina at rest o Vasospastic / Variant/ Prinzmetal's angina Caused by transient vasospasm of the coronary vessels Chest pain may develop at rest / sleep. CORONARY ARTERY PATHOLOGY. Increased workload on the heart Decreased oxygen supply to the heart Antianginal drugs ↑ Blood flow & ↓ oxygen demand ANTIANGINAL DRUGS: CLASSIFICATION 1. NITRATES: Short acting: Nitroglycerine, Isosorbide dinitrate (sublingual) Long acting: Isosorbide dinitrate (oral), Isosorbide mononitrate, Erythritol tetranitrate 2. β BLOCKERS: Metoprolol, Atenolol. 3. CALCIUM CHANNEL BLOCKERS: Nifedipine, Amlodipine, Nimodipine, Verapamil , Diltiazem. 4. POTASSIUM CHANNEL OPENERS: Nicorandil 5. OTHERS: Dipyridamole, Trimetazidine, Ranolazine, Ivabradine Mechanism of Action of Nitrates Nitrates are vasodilators ACTIONS OF NITRATES Peripheral vasodilation: Venodilation ↓ venous return ↓ preload myocardial workload ↓ ↓ oxygen demand ↓ ↓ Arterial dilation ↓ PVR ↓ afterload Redistribution of coronary blood flow: Decreased preload improves subendocardial perfusion Pharmacokinetic Properties of Organic Nitrates GTN / NITROGLYCERINE ISOSORBIDE DINITRATE Similar properties to GTN. Volatile liquid, T1/2 40min tabs stored in Last dose not to be taken later than 6pm. tightly closed glass bottles. ISOSORBIDE MONONITRATE High first pass ERYTHRITYL & PENTAERYTHRITOL TETRANITRATE metabolism • Longer acting, used for prophylaxis • Last dose to be taken in afternoon and SR tab once a day in morning. ADVERSE EFFECTS OF NITRO VASODILATORS The major acute adverse effects are due to excessive vasodilation Orthostatic hypotension Palpitations Severe throbbing headache Dizziness, sweating Flushing Syncope Drug Interactions: Sildenafil (PDE-5 inhibitor) used for erectile dysfunction can potentiate the actions of nitrovasodilators severe hypotension {because they inhibit the breakdown of cGMP (they should not be taken within 24 hours of taking a nitrovasodilator) } TOLERANCE WITH NITROVASODILATORS Continuous or frequent exposure can lead to the development of complete tolerance Nitrate-free periods of at least 8 hrs (e.g.- overnight) are recommended to avoid or reduce tachyphylaxis Monday morning disease/sickness- in GTN, explosives factory workers. Sudden withdrawal has resulted in myocardial infarction, due to vasospasm. WITHDRAWAL OF NITRATES SHOULD BE GRADUAL. USES: 1. Angina pectoris Acute pain (stable) Tab. NTG 0.5mg SL, repeat 3 doses every 5min, prophylaxis- long acting nitrates. Acute prophylaxis- SL NTG 15min before exertional activities Unstable angina: Inj. NTG 5-10 µg/min IV infusion Variant angina – relieve vasospasm 2. Acute Myocardial Infarction (STEMI) - NTG slow IV infusion, (monitor for HR & BP) 3. CHF / CCF- ↓ preload 4. Others : Biliary colic, Esophageal spasm, Cyanide poisoning BETA-ADRENERGIC BLOCKERS Cardioselective agents preferred Beneficial effects 1. Negative Chronotropic action: prevent arrhythmias 2. Negative Inotropic ( work load) : Improve myocardial perfusion (more time spent in diastole) 3. Reduce myocardial O2 demand & benefit by reduce risk of impending MI/sudden cardiac death. 4. Favorable redistribution of blood flow in the ischemic subendocardial region 18 Atenolol, Metoprolol Caution: should be taken on regular basis. No abrupt withdrawal after chronic use, may ppt MI β blocker withdrawal syndrome AVOID BETA BLOCKERS IF: PR interval (ECG) >0.24 s 2° or 3° atrioventricular block Heart rate <60 beats/min Blood pressure <90 mmHg Shock Left ventricular failure with congestive heart failure Severe reactive airway disease CALCIUM CHANNEL BLOCKERS CLASSIFICATION: i) Dihydropyridines: Nifedipine, Felodipine, Amlodipine, Nitrendipine, Nimodipine, Lacidipine, Clevidipine, Clinidipine ii) Phenyl alkylamines: Verapamil. iii) Benzothiazepine: Diltiazem. CALCIUM CHANNELS: TYPES Location Cardiac & smooth 1) Voltage sensitive Ca++ Channels: muscle, SAN, AVN L (long lasting) type Regulate- excitation contraction T( transient) type coupling; conduction velocity N (neuronal) type. 2) Receptor operated Ca++ Channels 3) Leak Channels or stretch operated channels + ++ 4) Na - Ca Exchange channel CCB’S CALCIUM CHANNEL BLOCKERS Nefidepine, verapamil, Diltiazem Cardiac effects Vascular effects NIFEDIPINE: Rapid onset, short duration Decreases PVR, BP falls Reflex Tachycardia (Reflex sympathetic stimulation of heart). ADR: palpitations, flushing, ankle edema, hypotension, headache, drowsiness, voiding difficulty in elderly males, hampers DM. Dose: 5, l0 mg tab; 10, 20, 30 mg SR tab Felodipine, Lacidipine: : long t1/2 Amlodipine: slow oral abs, peak after 6-9hrs, BA higher, t1/2 is longer 35-45hrs. Nitrendipine: releases NO from endothelium & inhibit cAMP PDE. It retards atherosclerosis. Nimodipine: short acting, penetrates BBB, selectively relaxes cerebral vasculature. Approved in trt of SAH, Congenital Intracranial aneurysms. CA++ CHANNEL BLOCKERS: DRUG INTERACTIONS Avoid -blockers in combination with verapamil, diltiazem Bradycardia, AV block Avoid Verapamil & Diltiazem- increase in plasma digoxin levels AV block can also occur USES OF CCB’S: 1) Chronic stable angina- prophylaxis, variant angina- DOC, verapamil, amlodipine - relieve spasm 2) Hypertension- long acting DHP’s gp..EX: Tab Amlodipine 3) Cardiac arrhythmias- Verapamil & Diltiazem are highly effective in PSVT and supraventricular tachyarrhythmias. 4) Hypertropic cardiomyopathy- Verapamil/ Diltiazem 5) Others: Premature labor (Nifedipine), Migraine (verapamil), Nocturnal leg cramps, (verapamil), Raynaud’s disease( DHP’s). OTHER ANTIANGINAL DRUGS: DIPYRIDAMOLE Powerful coronary dilator, Inhibits platelet aggregation increases blood flow by preventing uptake and degradation of adenosine USES: prophylaxis of coronary & cerebral thrombosis Dilates resistance vessels but no effect on large conducting coronary vessels ‘ Coronary steal phenomena’ TRIMETAZIDINE (* PFOX INHIBITOR/ METABOLIC MODULATORS) IMPROVE CELLULAR TOLERANCE TO ISCHAEMIA. MOA: Inhibits Mitochondrial LC3-KAT enzyme in fatty acid oxidation = ↓ FA metabolism increases glucose metabolism in myocardium. Prevents superoxide induced cytotoxicity to myocardial cells (cardioprotective) PK: absorbed orally, t1/2 6hrs SE: gastric burning, dizziness, fatigue & muscle cramps Uses: • Add on drug in Angina and Post MI patients along with conventional drugs *pFOX: partial Fatty acid OXidation pathway DRUG THERAPY IN ACUTE MI (STEMI): Includes 1. Diagnosis of MI- Symptoms/signs Serial ECG changes Cardiac enzyme markers 2. Immediate Medical Management ( emergency care) Treatment of complications of MI 3. Post MI drug therapy (prophylaxis) 4. Post MI life style management IMMEDIATE MEDICAL MANAGEMENT 1) Analgesia – Morphine or pethidine + antiemetic - IV • reduce sympathetic activity↓↓↓ myocardial O2 consumption, vascular resistance, BP, infarct size & arrhythmias Allay anxiety 2) Sublingual GTN 0.5mg (prevent an impending MI) 3) Tab Aspirin 300mg/ Tab Clopidogrel 300mg stat dose 4) High flow Oxygen by nasal prongs Streptokinase, Anistreplase, THROMBOLYTIC DRUGS – Alteplase, Reteplase Tenecteplase, urokinase Greatest benefit if given within first 1-2hrs MOA (Golden period is initial 60 min) Limit infarct size & mortality If primary PCI available: preferred EARLY MEDICAL MANAGEMENT 6) Prevention and treatment of arrhythmias prophylactic IV infusion of β blockers (unless contraindicated) – Metoprolol 5-15mg IV/ 50-100mg PO “reduce arrhythmias and infarct size” & mortality If Tachyarrhythmias- lidocaine, procainamide Bradyarrhythmias & heart block- atropine, electric pacing. 7) Maintenance of blood volume & Correction of acidosis– do not volume overload POST MI DRUG THERAPY (FOR PREVENTION OF FUTURE ATTACKS) Chronic prophylaxis drugs – life long Antiplatelet drugs • Aspirin 75-150mg/day ±Clopidogrel 75mg/day • Prevent arrhythmias & reinfarction β blockers 1 • Tab Metoprolol 50mg BID ACE Inhibitors/ • Prevention of cardiac remodeling and Angiotensin Receptor subsequent CHF, improve survival. Blockers • Tab. Ramipril 2.5mg BD, Tab.Valsartan 40-160mg BD • Hypolipidaemic & anti-inflammatory activity Statins cardioprotective • ex Tab Simvastatin 20-80mg/day POST MI LIFESTYLE MODIFICATION SURGICAL INTERVENTIONS (REVASCULARIZATION) PTCA (Percutaneous transluminal coronary angioplasty)- Balloon angioplasty Process of dilating coronary artery stenosis by an inflatable balloon introduced into arterial circulation via femoral / brachial/ radial artery. Coronary angiography showing a severe proximal
Load more

Recommended publications
  • Some Observations on the Atrial Sound*
    15 Oktober 1960 S.A. TYDSKRIF VIR GENEESKUNDE 887 SOME OBSERVATIONS ON THE ATRIAL SOUND* JOHN R BARLOW, M.R, RCH., M.R.C.P., Department of Medicine, University of The WiTwaTersralld. Johallllesburg The atrial sound, also known as the fourth heart sound Emotional factors probably play a large part in this; the or. presystolic gallop, has been defined' as an audible P-G interval may quickly horten again on the introduction ibration occurring more than 0·07 second after the of an intravenous needle or imilar procedure. beginning of the P wave of the simultaneous electrocardio­ 3. EffeCT of respiration. Whereas re piration produce gram (ECG) but preceding the onset of the QRS complex. no effect on the P-G interval in patients with hyperten ion It has been shown' that, unrelated to any alteration in the or ischaemia. the atrial sound of cor pulmonale both in­ P-R interval, the position of the atrial sound varies in creases in intensity and occurs earlier in the cardiac cycle relation to the first heart sound and to the simultaneous during inspiration as compared with expiration (Fig. 4). ECG. 4. EffeCT of various procedures. Jt has already been Jt is the purpose of this paper to demonstrate this mentioned that the intravenous administration of hypo­ variation in the timing of the atrial sound and to discuss tensive drugs will increase the P-G interval in hypertensive some of the clinical implications resulting from this varia­ patients. The inhalation of amyl nitrite has a similar effect bility. in hypertension (Fig. 5), though a change in the P-G METHODS AND OBSERVATIO S interval is seldom seen in cases with ischaemic heart disease following inhalation of this drug.
    [Show full text]
  • Chronotropic and Dromotropic Responses to Localized Glutamate Microinjections in the Rat $ Nucleus Ambiguus
    brain research 1542 (2014) 93–103 Available online at www.sciencedirect.com www.elsevier.com/locate/brainres Research Report Chronotropic and dromotropic responses to localized glutamate microinjections in the rat $ nucleus ambiguus Karla N. Sampaio1,He´lder Mauad2, K. Michael Spyer, Timothy W. Fordn Division of Biosciences, Faculty of Life Sciences, University College London, Gower Street, London WC1E 6BT, UK article info abstract Article history: The cardioinhibitory effects of cardiac vagal motoneurons (CVMs) are mediated by Accepted 18 October 2013 activation of postganglionic neurons in the epicardial ganglia which have been shown to Available online 24 October 2013 exert functionally selective effects on heart rate and atrioventricular conduction in the rat. Here we investigate whether CVMs producing these responses may occupy different Keywords: rostrocaudal positions within the nucleus ambiguus. Excitation of CVMs was attempted Autonomic nervous system by microinjections of glutamate into the nucleus ambiguus of an arterially perfused Vagus nerve preparation in a grid extending over 2 mm in the rostrocaudal plane using the obex as a Nucleus ambiguus reference point. Microinjections were paired, one made during pacing to measure changes Heart rate in atrioventricular conduction (P-R interval) independent of changes in heart rate and the Glutamate other looking for changes in heart period (P-P interval) un-paced. Although evidence of a differential distribution was found in 7 cases, in the majority (13/20), sites producing maximal effects on both variables coincided. Maximal changes in atrioventricular conduc- tion resulted from more rostral sites in 6 cases and from a more caudal site in only one. Overall, the ratio of the change in atrioventricular conduction to the change in heart rate for a given site was significantly greater 1 mm rostral to the obex than at either end of the test grid.
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • A Textbook of Clinical Pharmacology and Therapeutics This Page Intentionally Left Blank a Textbook of Clinical Pharmacology and Therapeutics
    A Textbook of Clinical Pharmacology and Therapeutics This page intentionally left blank A Textbook of Clinical Pharmacology and Therapeutics FIFTH EDITION JAMES M RITTER MA DPHIL FRCP FMedSci FBPHARMACOLS Professor of Clinical Pharmacology at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK LIONEL D LEWIS MA MB BCH MD FRCP Professor of Medicine, Pharmacology and Toxicology at Dartmouth Medical School and the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA TIMOTHY GK MANT BSC FFPM FRCP Senior Medical Advisor, Quintiles, Guy's Drug Research Unit, and Visiting Professor at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK ALBERT FERRO PHD FRCP FBPHARMACOLS Reader in Clinical Pharmacology and Honorary Consultant Physician at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK PART OF HACHETTE LIVRE UK First published in Great Britain in 1981 Second edition 1986 Third edition 1995 Fourth edition 1999 This fifth edition published in Great Britain in 2008 by Hodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK, 338 Euston Road, London NW1 3BH http://www.hoddereducation.com ©2008 James M Ritter, Lionel D Lewis, Timothy GK Mant and Albert Ferro All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency.
    [Show full text]
  • Basic Rhythm Recognition
    Electrocardiographic Interpretation Basic Rhythm Recognition William Brady, MD Department of Emergency Medicine Cardiac Rhythms Anatomy of a Rhythm Strip A Review of the Electrical System Intrinsic Pacemakers Cells These cells have property known as “Automaticity”— means they can spontaneously depolarize. Sinus Node Primary pacemaker Fires at a rate of 60-100 bpm AV Junction Fires at a rate of 40-60 bpm Ventricular (Purkinje Fibers) Less than 40 bpm What’s Normal P Wave Atrial Depolarization PR Interval (Normal 0.12-0.20) Beginning of the P to onset of QRS QRS Ventricular Depolarization QRS Interval (Normal <0.10) Period (or length of time) it takes for the ventricles to depolarize The Key to Success… …A systematic approach! Rate Rhythm P Waves PR Interval P and QRS Correlation QRS Rate Pacemaker A rather ill patient……… Very apparent inferolateral STEMI……with less apparent complete heart block RATE . Fast vs Slow . QRS Width Narrow QRS Wide QRS Narrow QRS Wide QRS Tachycardia Tachycardia Bradycardia Bradycardia Regular Irregular Regular Irregular Sinus Brady Idioventricular A-Fib / Flutter Bradycardia w/ BBB Sinus Tach A-Fib VT PVT Junctional 2 AVB / II PSVT A-Flutter SVT aberrant A-Fib 1 AVB 3 AVB A-Flutter MAT 2 AVB / I or II PAT PAT 3 AVB ST PAC / PVC Stability Hypotension / hypoperfusion Altered mental status Chest pain – Coronary ischemic Dyspnea – Pulmonary edema Sinus Rhythm Sinus Rhythm P Wave PR Interval QRS Rate Rhythm Pacemaker Comment . Before . Constant, . Rate 60-100 . Regular . SA Node Upright in each QRS regular . Interval =/< leads I, II, . Look . Interval .12- .10 & III alike .20 Conduction Image reference: Cardionetics/ http://www.cardionetics.com/docs/healthcr/ecg/arrhy/0100_bd.htm Sinus Pause A delay of activation within the atria for a period between 1.7 and 3 seconds A palpitation is likely to be felt by the patient as the sinus beat following the pause may be a heavy beat.
    [Show full text]
  • Electrocardiography: a Technologist's Guide to Interpretation
    CONTINUING EDUCATION Electrocardiography: A Technologist’s Guide to Interpretation Colin Tso, MBBS, PhD, FRACP, FCSANZ1,2, Geoffrey M. Currie, BPharm, MMedRadSc(NucMed), MAppMngt(Hlth), MBA, PhD, CNMT1,3, David Gilmore, ABD, CNMT, RT(R)(N)3,4, and Hosen Kiat, MBBS, FRACP, FACP, FACC, FCCP, FCSANZ, FASNC, DDU1,2,3,5 1Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia; 2Cardiac Health Institute, Sydney, New South Wales, Australia; 3Faculty of Science, Charles Sturt University, Wagga Wagga, New South Wales, Australia; 4Faculty of Medical Imaging, Regis College, Boston, Massachusetts; and 5Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia CE credit: For CE credit, you can access the test for this article, as well as additional JNMT CE tests, online at https://www.snmmilearningcenter.org. Complete the test online no later than December 2018. Your online test will be scored immediately. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive 1.0 CEH (Continuing Education Hour) credit. SNMMI members will have their CEH credit added to their VOICE transcript automatically; nonmembers will be able to print out a CE certificate upon successfully completing the test. The online test is free to SNMMI members; nonmembers must pay $15.00 by credit card when logging onto the website to take the test. foundation for understanding the science of electrocardiog- The nuclear medicine technologist works with electrocardio- raphy and its interpretation. graphy when performing cardiac stress testing and gated cardiac imaging and when monitoring critical patients.
    [Show full text]
  • Medical Management of Advanced Heart Failure
    CLINICAL CARDIOLOGY CLINICIAN’S CORNER Medical Management of Advanced Heart Failure Anju Nohria, MD Context Advanced heart failure, defined as persistence of limiting symptoms de- Eldrin Lewis, MD spite therapy with agents of proven efficacy, accounts for the majority of morbidity and mortality in heart failure. Lynne Warner Stevenson, MD Objective To review current medical therapy for advanced heart failure. EART FAILURE HAS EMERGED AS Data Sources We searched MEDLINE for all articles containing the term advanced a major health challenge, in- heart failure that were published between 1980 and 2001; EMBASE was searched from creasing in prevalence as age- 1987-1999, Best Evidence from 1991-1998, and Evidence-Based Medicine from 1995- adjusted rates of myocardial 1999. The Cochrane Library also was searched for critical reviews and meta-analyses Hinfarction and stroke decline.1 Affect- of congestive heart failure. ing 4 to 5 million people in the United Study Selection Randomized controlled trials of therapy for 150 patients or more States with more than 2 million hospi- were included if advanced heart failure was represented. Other common clinical situ- talizations each year, heart failure alone ations were addressed from smaller trials as available, trials of milder heart failure, con- accounts for 2% to 3% of the national sensus guidelines, and both published and personal clinical experience. health care budget. Developments her- Data Extraction Data quality was determined by publication in peer-reviewed lit- alded in the news media increase pub- erature or inclusion in professional society guidelines. lic expectations but focus on decreas- Data Synthesis A primary focus for care of advanced heart failure is ongoing iden- ing disease progression in mild to tification and treatment of the elevated filling pressures that cause disabling symp- moderate stages2,3 or supporting the cir- toms.
    [Show full text]
  • The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
    Pharmacology & Therapeutics 178 (2017) 67–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: M. Curtis The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Ahmed Selim, Ronald Zolty, Yiannis S. Chatzizisis ⁎ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA article info abstract Available online 21 March 2017 Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many Keywords: other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery Heart failure of treatments to improve the survival and quality of life of patients with heart failure; many were successful, Reduced ejection fraction while others failed. Given that most of the successes in treating heart failure were achieved in patients with re- Pharmacotherapy duced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of Novel drugs HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate poten- tial treatment targets and pathways that might play a role in treating HFrEF in the future. © 2017 Elsevier Inc. All rights reserved. Contents 1. Introduction..............................................
    [Show full text]
  • Investigations Into the Role of Nitric Oxide in Disease
    INVESTIGATIONS INTO THE ROLE OF NITRIC OXIDE IN CARDIOVASCULAR DEVXLOPMENT DISEASE: INSIGHTS GAINED FROM GENETICALLY ENGINEERED MOUSE MODELS OF HUMAN DISEASE Tony Lee A thesis submitted in conformity with the requirements for the degree of Master's of Science Institute of Medicai Science University of Toronto @ Copyright by Tony C. Lee (2000) National Library Bibliothèque nationale I*I of Canada du Canada Acquisitions and Acquisitions et Bibliogaphic Services services bibliogaphiques 395 Wellington Street 395, rue Wellington Ottawa ON K1A ON4 Ottawa ON KIA ON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies of this thesis in microfonn, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/nlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or othewise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. INVESTIGATIONS INTO THE ROLE OF MTNC OXIDE IN CARDIOVASCULAR DEVELOPMENT AND DISEASE: INSIGHTS GAiNED FROM GENETICALLY ENGINEERED MOUSE MODELS OF HUMAN DISEASE B y Tony Lee A thesis submitted in conformity with the requirements for the degree of Master's of Science (2000) Instinite of Medical Science, University of Toronto In the first expenmental series, the antiatherosclerotic effects of Enalûpril vrrsus Irbesartan were compared in the LDL-R knockout mouse model.
    [Show full text]
  • Hair Growth Stimulation with Nitroxide and Other Radicals
    Europaisches Patentamt 263 European Patent Office © Publication number: 0 327 Office europeen des brevets A1 © EUROPEAN PATENT APPLICATION © Application number: 89300785.6 © Int. CI.4: A61 K 7/06 , A61K 47/00 © Date of filing: 27.01.89 © Priority: 29.01.88 US 149720 © Applicant: PROCTOR, Peter H. Twelve Oaks Medical Tower 4125 Southwest © Date of publication of application: Freeway 09.08.89 Bulletin 89/32 Suite 1616 Houston, TX 77027(US) © Designated Contracting States: © Inventor: PROCTOR, Peter H. AT BE CH OE ES FR GB GR IT Li LU NL SE Twelve Oaks Medical Tower 4125 Southwest Freeway Suite 1616 Houston, TX 77027(US) © Representative: Gore, Peter Manson et al W.P. THOMPSON & CO. Coopers Building Church Street Liverpool L1 3AB(GB) © Hair growth stimulation with nitroxide and other radicals. © Hair growth stimulation with nitroxide and other radicals. A nitroxide radical source compound is applied topically with an adjuvant selected from reducing agents, hydroxyl radical scavengers and antioxidants to activate formation of the nitroxide radical and/or to protect the nitroxide radical from reaction with other free radicals. Also disclosed is a kit for preparing a unit dose for topical application of a nitric oxide generating compound and a reducing agent reactive therewith to form nitric oxide on or in the skin. Other adjuvants include SOD and antiandrogens. Various other radical-forming hair growth stimulants and preparations thereof are disclosed. < w CO CM IN CM CO © Q. Ill Xerox Copy Centre EP 0 327 263 A1 rIAIR GROWTH STIMULATION WITH NITROXIDE AND OTHER RADICALS This invention relates to a composition and method for stimulating hair growth, and to a kit for preparation of such a composition.
    [Show full text]
  • Short PR Intervals and Tachyarrhythmias in Fabry's Disease
    Postgraduate Medical Journal (1986) 62, 285-287 Postgrad Med J: first published as 10.1136/pgmj.62.726.285 on 1 April 1986. Downloaded from Clinical Reports Short PR intervals and tachyarrhythmias in Fabry's disease J. Efthimiou, J. McLelland and D.J. Betteridge Department ofMedicine, University College Hospital, London WCJE6JJ, UK. Summary: Two brothers with Fabry's disease presenting with palpitations were found to have intermittent supraventricular tachycardias. Their electrocardiograms, when symptom-free, revealed short PR intervals consistent with ventricular pre-excitation. Treatment of one of the brothers with verapamil resulted in improvement of the palpitations and reduction in frequency of the tachycardia. Recurrent supraventricular tachycardia associated with ventricular pre-excitation has not previously been described in Fabry's disease. Evidence suggests that this complication may be due to glycolipid deposition in the conducting system around the atrioventricular node. Introduction Fabry's disease (angiokeratoma corporis diffusum) is evidence of heart failure. an X-linked disorder of glycolipid metabolism result The full blood count, erythrocyte sedimentation ing in deposition ofceramide trihexoside, particularly rate, plasma electrolytes, cardiac enzymes, thyroid in the skin, kidneys and cardiovascular system. Car- function tests and chest radiograph were normal. The copyright. diac manifestations are numerous and include rhythm creatinine clearance was reduced at 51 ml/min, but disturbances, myocardial infarction, and congestive or urine analysis was normal with no proteinuria. The rarely hypertrophic cardiomyopathy (Colucci et al., electrocardiogram revealed a short PR interval (0.10 s) 1982). with no delta wave (Figure 1). Electrocardiograms We report on two brothers known to have Fabry's recorded 12 and 5 years earlier revealed normal PR disease who had intermittent tachyarrhythmias with intervals of0.16 s and 0.12 s respectively.
    [Show full text]
  • Basic Cardiac Rhythms – Identification and Response Module 1 ANATOMY, PHYSIOLOGY, & ELECTRICAL CONDUCTION Objectives
    Basic Cardiac Rhythms – Identification and Response Module 1 ANATOMY, PHYSIOLOGY, & ELECTRICAL CONDUCTION Objectives ▪ Describe the normal cardiac anatomy and physiology and normal electrical conduction through the heart. ▪ Identify and relate waveforms to the cardiac cycle. Cardiac Anatomy ▪ 2 upper chambers ▪ Right and left atria ▪ 2 lower chambers ▪ Right and left ventricle ▪ 2 Atrioventricular valves (Mitral & Tricuspid) ▪ Open with ventricular diastole ▪ Close with ventricular systole ▪ 2 Semilunar Valves (Aortic & Pulmonic) ▪ Open with ventricular systole ▪ Open with ventricular diastole The Cardiovascular System ▪ Pulmonary Circulation ▪ Unoxygenated – right side of the heart ▪ Systemic Circulation ▪ Oxygenated – left side of the heart Anatomy Coronary Arteries How The Heart Works Anatomy Coronary Arteries ▪ 2 major vessels of the coronary circulation ▪ Left main coronary artery ▪ Left anterior descending and circumflex branches ▪ Right main coronary artery ▪ The left and right coronary arteries originate at the base of the aorta from openings called the coronary ostia behind the aortic valve leaflets. Physiology Blood Flow Unoxygenated blood flows from inferior and superior vena cava Right Atrium Tricuspid Valve Right Ventricle Pulmonic Valve Lungs Through Pulmonary system Physiology Blood Flow Oxygenated blood flows from the pulmonary veins Left Atrium Mitral Valve Left Ventricle Aortic Valve Systemic Circulation ▪ Blood Flow Through The Heart ▪ Cardiology Rap Physiology ▪ Cardiac cycle ▪ Represents the actual time sequence between
    [Show full text]